Roche H1 2026: Phase III Divarasib Headline Masks Unresolved HTA Bar; Giredestrant and Enspryng Carry Distinct Evidence Gaps

Roche Reports Strong H1 2026 Sales and Key Regulatory Milestones

Roche reported robust financial performance in the first half of 2026, with Group sales increasing by 6% at constant exchange rates (CER) to CHF 30.4 billion. However, reported sales in CHF decreased by 2% due to the significant appreciation of the Swiss franc. The Pharmaceuticals Division grew 6% at CER, driven by strong demand for key medicines, while the Diagnostics Division achieved 3% CER growth. The company also announced significant pipeline advancements, including five US FDA Priority Reviews for drugs like giredestrant in early-stage breast cancer and Enspryng in thyroid eye disease, positive Phase III data for divarasib in lung cancer, and the launch of the Axelios 1 sequencing platform.

• Roche demonstrated strong financial results in H1 2026, with Group sales rising 6% at constant exchange rates (CER) to CHF 30.4 billion, and core operating profit increasing 10% at CER. This growth was primarily driven by a 6% CER increase in the Pharmaceuticals Division and a 3% CER increase in the Diagnostics Division, despite a 2% decline in reported CHF sales due to currency fluctuations.
• The company achieved significant regulatory milestones, securing five US FDA Priority Reviews for key assets. These include giredestrant for early-stage ER-positive breast cancer, Enspryng for thyroid eye disease, Tecentriq for stage III colon cancer, and Gazyva/Gazyvaro for idiopathic nephrotic syndrome and primary membranous nephropathy, underscoring accelerated progress in diverse therapeutic areas.
• Roche advanced its pipeline with positive Phase III data for divarasib, showing superiority against approved KRAS G12C inhibitors in non-small cell lung cancer, and promising Phase III results for fenebrutinib in multiple sclerosis. Additionally, the Diagnostics Division launched the transformative Axelios 1 next-generation sequencing platform and received CE marks for the Elecsys pTau217 blood test for Alzheimer’s pathology and the Elecsys IGRA TB test for tuberculosis infection.

Why New Options Are Needed for ER-Positive Early Breast Cancer

Despite meaningful advances in systemic and locoregional treatment, early-stage breast cancer management continues to face several unresolved challenges that affect both oncological outcomes and patient quality of life. Adherence to established therapies remains a persistent concern, and the heterogeneity of disease biology complicates uniform treatment strategies.

• Endocrine therapy adherence and adverse effects: Although adjuvant endocrine therapy (AET) reduces hormone receptor-positive (HR+) breast cancer recurrence by 30–50%, significant adverse effects — including vasomotor symptoms, bone loss, joint arthralgias, genitourinary syndrome of menopause, and low libido — pose a direct threat to treatment adherence. A nationwide French cohort study found that only 68.8% of women maintained continuous optimal adherence over 5 years, with extreme age (younger than 50 and older than 70 years) and switching AET identified as the main factors associated with nonadherence trajectories.

• Endocrine resistance: Many patients with HR+/HER2-negative breast cancer eventually encounter tumour relapse due to acquired resistance to endocrine agents, while others experience de novo resistance that limits efficacy from the outset. HER2 overexpression has been identified as a contributor to this resistance in oestrogen receptor-positive breast cancer, and the interaction between HER2-kinase inhibitors and endocrine treatment may differ from that of antibody-based HER2-targeted therapy.

• Long-term toxicities of adjuvant chemotherapy: There is insufficient information regarding the long-term sequelae of most chemotherapeutic agents used in the adjuvant setting. Long-term concerns include cardiac toxicity, secondary leukemia, cognitive function impairment, neurotoxicity, and effects on fertility and sexual function in younger patients. These adverse events are frequently overshadowed by the well-demonstrated clinical efficacy and reassuring short-term safety profiles of commonly used chemotherapy regimens.

• Radiotherapy de-escalation in younger patients: Radiotherapy de-escalation strategies — including ultra-hypofractionation, partial breast irradiation, and omission of radiotherapy — have largely been evaluated in older or postmenopausal populations. Younger women remain underrepresented in de-escalation trials despite exhibiting less favorable clinicopathological characteristics associated with increased locoregional recurrence and inferior survival. Evidence supporting more aggressive de-escalation in women under 50 years, particularly those under 40, remains less robust.

• Identifying high-risk patients for intensified endocrine therapy: Patients at high risk of recurrence may still experience early relapse under traditional adjuvant endocrine therapy, necessitating consideration of intensified approaches. Strategies such as combining ovarian function suppression, extending therapy duration, adding cyclin-dependent kinase 4/6 inhibitors, or incorporating bone-modifying drugs each carry their own evidence gaps and unresolved questions regarding optimal sequencing and patient selection. Additional research and time are described as essential to determine the optimal approaches for intensified adjuvant endocrine therapy.

Unpacking Giredestrant's Pivotal Phase III Trial Design

Several key adjuvant and neoadjuvant trials in early-stage breast cancer have shaped current treatment paradigms, each employing distinct eligibility criteria, intervention strategies, and primary endpoints. The table below summarizes the design parameters and endpoints across the trials addressed in the available literature.

PALLAS and PENELOPE-B reported no iDFS benefit with palbociclib, while monarchE and NATALEE demonstrated iDFS improvements with abemaciclib and ribociclib, respectively, leading to regulatory approvals. OS benefit has not yet been demonstrated in any of these adjuvant trials. In the neoadjuvant setting, the TQB2440 trial established equivalence to reference pertuzumab, with IRC-assessed tpCR of 58.9% versus 58.1% and a relative risk of 1.02 (90% confidence interval 0.89–1.16), entirely within the predefined equivalence margins. The I-SPY2 trial demonstrated that residual cancer burden carried consistent prognostic significance across all subtypes, with event-free survival worsening significantly per unit of RCB regardless of subtype or treatment.

The Evolving Landscape of Oral SERDs in Early Breast Cancer

Giredestrant belongs to the oral selective estrogen receptor degrader (SERD) class — pure estrogen receptor antagonists developed to overcome endocrine therapy resistance in estrogen receptor-positive (ER+) breast cancer. Several other oral SERDs sharing this mechanism of action are currently in published and ongoing clinical trials for the same indication.

The knowledge base does not have sufficient information on this aspect. regarding the specific intervention models for giredestrant's own trials; however, the table above reflects the intervention structures reported for the four comparator oral SERDs identified in the literature.

Note on trial design context: Combination strategies pairing oral SERDs with CDK4/6 inhibitors and other targeted agents are also under evaluation across this drug class, as reflected in the imlunestrant EMBER trial data and referenced ongoing combination trials.

Correction — removing the impermissible trailing note and reissuing the clean formatted output:

Giredestrant belongs to the oral selective estrogen receptor degrader (SERD) class — pure estrogen receptor antagonists developed to overcome endocrine therapy resistance in estrogen receptor-positive (ER+) breast cancer. Several other oral SERDs sharing this mechanism of action are in published and ongoing clinical trials for the same indication. The intervention models span monotherapy comparisons against standard endocrine therapy through to multi-arm combination regimens.

Giredestrant's Broader Pipeline Potential Beyond Early Breast Cancer

Giredestrant's clinical development extends into advanced and metastatic breast cancer settings, with evidence from the reviewed literature pointing to its evaluation in second-line metastatic disease and in combination regimens. The available evidence, however, does not detail specific intervention models or trial designs for indications beyond early-stage breast cancer in granular terms.

• Advanced/metastatic ER+ breast cancer: Giredestrant has been evaluated in the second-line metastatic setting. In the phase 2 SERENA-2 trial context, giredestrant is referenced alongside camizestrant and other oral SERDs as having been trialled in second-line metastatic disease, though giredestrant "failed to show PFS benefit in second line metastatic setting."

• Combination with CDK4/6 inhibition: Giredestrant has been studied in combination with palbociclib in ER+ breast cancer models. Genome-wide CRISPR screen data demonstrated that "depletion or inhibition of GPX4 increases sensitivity to palbociclib and giredestrant, and their combination, in ER+ breast cancer models," situating giredestrant within combination therapy investigation frameworks.

• ESR1 mutant and wild-type tumour models: Preclinical and translational work positions giredestrant for evaluation across both ESR1 mutant and wild-type ERα tumour contexts, with the compound inducing "tumor regressions either as a single agent or in combination with a CDK4/6 inhibitor in an ESR1 mutant PDX or a wild-type ERα tumor model."

• Phase III clinical trials: As of the 2021 publication, giredestrant was confirmed to be "being evaluated in Phase III clinical trials," though the specific indications and intervention models for those trials beyond early-stage breast cancer are not detailed in the available literature.

The knowledge base does not have sufficient information on this aspect.

Roche's Pipeline Momentum: Expanding Reach in Oncology and Autoimmune Disease

Roche's recent financial performance, coupled with a series of significant pipeline advancements, paints a picture of a company strategically fortifying its position across key therapeutic areas. The momentum in its Pharmaceuticals Division is largely driven by a diversified approach to innovation, particularly in oncology and autoimmune diseases.

Central to this strategy is giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD). Its US FDA Priority Review for early-stage breast cancer underscores the potential for this class of drugs to overcome resistance mechanisms common with traditional endocrine therapies. The ongoing heredERA BC trial further highlights a sophisticated strategy to co-target the HER2 and ER pathways in HER2+, ER+ breast cancer, aiming to optimize treatment impact. While early studies showed giredestrant to be well-tolerated, with dose-dependent asymptomatic bradycardia noted, the shift in oncology dose selection paradigms emphasizes optimizing safety alongside efficacy, suggesting a careful approach to its long-term clinical implementation.

Another significant development is the Priority Review for Enspryng (satralizumab) in thyroid eye disease (TED). This represents a strategic expansion for a drug already indicated for neuromyelitis optica spectrum disorder (NMOSD). By targeting IL-6 receptor signaling, Enspryng offers a potential disease-modifying treatment for TED, addressing a critical unmet need for durable systemic therapy. However, its noted delayed onset of action in NMOSD suggests that its utility in acute TED presentations might need careful consideration against therapies offering more rapid symptom control.

In the competitive landscape of targeted oncology, divarasib (GDC-6036) is emerging as a strong contender. Positive Phase III data in KRAS G12C-mutated lung cancer, demonstrating durable clinical responses and a manageable safety profile, positions it to capture a significant share of this growing market. The long-term follow-up data from its Phase I study further reinforces its potential, showing sustained antitumor activity. However, with other KRAS G12C inhibitors already available, divarasib's success will hinge on its ability to clearly differentiate its profile in terms of efficacy, safety, or patient convenience.

Finally, the launch of the Axelios 1 sequencing platform reinforces Roche's commitment to precision medicine. Advanced genomic profiling is increasingly vital for identifying patients who will benefit most from targeted therapies like divarasib, and for improving diagnostic accuracy. This integrated approach, combining innovative therapeutics with cutting-edge diagnostics, is crucial for navigating the complexities of modern drug development and patient care.